Drug Trial Radar · NCT04735536
Pilot Clinical Study of CT1812 in Mild to Moderate Alzheimer's Disease Using EEG
Last checked: Nov 19, 2026Latest source record: Nov 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
16
Actual
Start
Jul 9, 2020
Primary completion
Apr 26, 2023
Study completion Apr 26, 2023
Sponsor
- Lead sponsor
- Cognition TherapeuticsIndustry
- Sponsor type
- Industry
- Collaborators
- National Institute on Aging (NIA)
- First posted
- Feb 3, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a single-site, randomized, double-blind, placebo-controlled, 29-day, 2-period crossover Phase 2 study of 1 dose level of CT1812 (active) or placebo in adults with mild to moderate AD.
Conditions
- Alzheimer Disease
Interventions
CT1812Drug
Active Treatment- CT1812 at a dose of 300mg
PlaceboOther
Placebo Comparator
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of TEAEs, Related TEAEs, SAEs, and Related SAEsTime frame: Up to 126 days
- Change in the Brain Activity Reflected by Changes of Spectral Power in Conventional Frequency Bands Measured by the Global Relative Theta (4-8 Hz) Power Obtained Through EEG Assessment.Time frame: Day 1 through Day 29 of Period 1 and Day 1 (study day 44) and Day 29 (study day 72) of Period 2
- Changes in Predose CT1812 Plasma Concentrations.Time frame: Baseline through Day 84: Pre and Post- Dose on Days 1, 29 AND Pre Dose Days 8, 15, 22.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Brain Research Center
Amsterdam, Netherlands
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.